Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET) has radically altered the landscape of imaging and therapeutic decision-making in prostate cancer. For certain applications within prostate cancer, including initial staging and biochemical recurrence, PSMA PET is undoubtedly a new standard-of-care. However, as with any new imaging modality, interpretation has important pitfalls. Those pitfalls must be considered when approaching PSMA PET in order to optimize its role in guiding patient management. Dr. Rowe will discuss the accepted indications for PSMA PET as well as strategies for mitigating interpretive pitfalls.